The Department of Health and Human Services’ Administration for Strategic Preparedness and Response June 5 announced it selected two locations to test an automated, point-of-care, sterile saline manufacturing system that could help prevent or mitigate intravenous fluid shortages in the U.S. The system, called Caspian, began development in 2019. One unit will be tested at Walter Reed Medical Center in Bethesda, Md., while the other will be tested and reviewed by the Food and Drug Administration. ASPR has been working with Manchester, N.H.-based DEKA Research and Development Corp. on manufacturing the units, with the intent of producing up to 500 bags of IV fluid per day.

Related News Articles

Headline
President Trump, late Sept. 25, announced that starting Oct. 1, the U.S. will impose a 100% tariff on any branded or patented pharmaceutical product, unless a…
Headline
The Department of Commerce Sept. 24 released a notice seeking public comment on an investigation it launched Sept. 2 on imports of personal protective…
Headline
The Food and Drug Administration has identified a Class I recall of certain Olympus ViziShot 2 FLEX Needles due to a possible patient safety issue caused by a…
Headline
The White House Sept. 5 issued an executive order modifying the scope of reciprocal tariffs announced in April to establish a framework of trade deals with…
Headline
A JAMA study published Aug. 20 found that nearly 63% of all U.S. drug production facilities from 2019 through 2024 were in counties where a weather disaster…
Headline
B. Braun Medical has voluntarily recalled two lots of Lactated Ringer’s Injection USP 1000 mL and 0.9% Sodium Chloride Injection USP 1000 mL IV fluids due to…